Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;18(5):1107-14.
doi: 10.1002/pro.91.

Structure of a mutant human purine nucleoside phosphorylase with the prodrug, 2-fluoro-2'-deoxyadenosine and the cytotoxic drug, 2-fluoroadenine

Affiliations

Structure of a mutant human purine nucleoside phosphorylase with the prodrug, 2-fluoro-2'-deoxyadenosine and the cytotoxic drug, 2-fluoroadenine

Sepideh Afshar et al. Protein Sci. 2009 May.

Abstract

A double mutant of human purine nucleoside phosphorylase (hDM) with the amino acid mutations Glu201Gln:Asn243Asp cleaves adenosine-based prodrugs to their corresponding cytotoxic drugs. When fused to an anti-tumor targeting component, hDM is targeted to tumor cells, where it effectively catalyzes phosphorolysis of the prodrug, 2-fluoro-2'-deoxyadenosine (F-dAdo) to the cytotoxic drug, 2-fluoroadenine (F-Ade). This cytotoxicity should be restricted only to the tumor microenvironment, because the endogenously expressed wild type enzyme cannot use adenosine-based prodrugs as substrates. To gain insight into the interaction of hDM with F-dAdo, we have determined the crystal structures of hDM with F-dAdo and F-Ade. The structures reveal that despite the two mutations, the overall fold of hDM is nearly identical to the wild type enzyme. Importantly, the residues Gln201 and Asp243 introduced by the mutation form hydrogen bond contacts with F-dAdo that result in its binding and catalysis. Comparison of substrate and product complexes suggest that the side chains of Gln201 and Asp243 as well as the purine base rotate during catalysis possibly facilitating cleavage of the glycosidic bond. The two structures suggest why hDM, unlike the wild-type enzyme, can utilize F-dAdo as substrate. More importantly, they provide a critical foundation for further optimization of cleavage of adenosine-based prodrugs, such as F-dAdo by mutants of human purine nucleoside phosphorylase.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Overall structure of trimeric hDM. In each monomer, β-sheets are in yellow and loops are in green. α-helices are shown in red, except for the two helices F and H of each monomer shown in navy. F-dAdo is shown as sticks. (B) One subunit of hDM complexed with F-dAdo is superimposed on one subunit of hPNP complexed with guanosine (1RFG) and unliganded hPNP (1ULA). hDM is shown in navy, hPNP complexed with guanosine is green, and uncomplexed hPNP is red. In F-dAdo and guanosine, shown as sticks, carbons are in yellow and green, respectively. In both molecules, nitrogens are navy, oxygens red, and fluorine is light blue. The flexible loop, 241–265, is indicated by an asterisk.
Figure 2
Figure 2
Interaction of hDM with F-dAdo, phosphate/sulfate, and F-Ade. In hDM, carbons are shown in light gray, oxygens in red, and nitrogens in navy. Water molecule is shown as red sphere. In F-dAdo and F-Ade, Fluorine is shown in light blue and carbons in yellow and green, respectively. Sulfate is shown in yellow. (A) A close overview of hDM binding to F-dAdo and sulfate which is bound to the phosphate binding site. (B) A close overview of hDM binding to F-Ade. (C) Base binding pocket of hDM complexed to F-dAdo or F-Ade superimposed. (D) Base binding pocket of hDM complexed with F-dAdo, shown in yellow is superimposed on the structure of hPNP complexed with guanosine, shown in pink (1RFG). (E and F) Simulated annealing Fo-Fc omits maps calculated with CNS. Blue and red contours drawn at +3.5 and −3.5 sigma levels.
Figure 3
Figure 3
Proposed mechanism for cleavage of F-dAdo to F-Ade by hDM.

References

    1. Voeks D, Martiniello-Wilks R, Madden V, Smith K, Bennetts E, Both GW, Russell PJ. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther. 2002;9:759–768. - PubMed
    1. Parker WB, Allan PW, Hassan A, Secrist JA, III, Sorscher EJ, Waud WR. Antitumor activity of 2-fluoro-20-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther. 2003;10:23–29. - PubMed
    1. Afshar S, Asai T, Morrison SL. Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer. MCT. 2009;8:1–9. - PMC - PubMed
    1. Stoeckler JD, Poirot AF, Smith RM, Parks JRE, Ealick SE, Takabayashi K, Erion MD. Purine nucleoside phosphorylase. 3. Reversal of purine base specificity by site-directed mutagenesis. Biochemistry. 1997;36:11749–11756. - PubMed
    1. Koellner G, Bzowska A, Wielgus-Kutrowska B, Luic M, Steiner T, Saenger W, Stepinski J. Open and closed conformation of the E. coli purine nucleoside phosphorylase active center and implications for the catalytic mechanism. J Mol Biol. 2002;315:351–371. - PubMed

Publication types

MeSH terms

LinkOut - more resources